Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLRB NYSEAMERICAN:CVM OTCMKTS:INBP NASDAQ:PLUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLRBCellectar Biosciences$2.47-4.3%$2.74$2.20▼$6.52$19.74M0.55513,751 shs36,527 shsCVMCel-Sci$1.23-1.6%$1.26$0.89▼$13.48$21.50M0.64277,042 shs193,001 shsINBPIntegrated BioPharma$0.16+2.3%$0.18$0.14▼$0.42$5.08M0.3510,989 shs995 shsPLURPluri$1.85-5.1%$2.25$1.56▼$5.68$19.96M0.6415,678 shs27,933 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLRBCellectar Biosciences+2.38%-1.90%-7.53%-10.42%-50.67%CVMCel-Sci-1.57%+8.70%+20.19%-62.57%-71.26%INBPIntegrated BioPharma0.00%-1.78%-15.25%-39.13%-48.35%PLURPluri+7.14%+16.07%-3.47%-41.88%-61.61%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLRBCellectar Biosciences$2.47-4.3%$2.74$2.20▼$6.52$19.74M0.55513,751 shs36,527 shsCVMCel-Sci$1.23-1.6%$1.26$0.89▼$13.48$21.50M0.64277,042 shs193,001 shsINBPIntegrated BioPharma$0.16+2.3%$0.18$0.14▼$0.42$5.08M0.3510,989 shs995 shsPLURPluri$1.85-5.1%$2.25$1.56▼$5.68$19.96M0.6415,678 shs27,933 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLRBCellectar Biosciences+2.38%-1.90%-7.53%-10.42%-50.67%CVMCel-Sci-1.57%+8.70%+20.19%-62.57%-71.26%INBPIntegrated BioPharma0.00%-1.78%-15.25%-39.13%-48.35%PLURPluri+7.14%+16.07%-3.47%-41.88%-61.61%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLRBCellectar Biosciences 2.80Moderate Buy$11.00345.34% UpsideCVMCel-Sci 0.00N/AN/AN/AINBPIntegrated BioPharma 0.00N/AN/AN/APLURPluri 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest INBP, CVM, CLRB, and PLUR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026CLRBCellectar Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/12/2026CLRBCellectar Biosciences Brookline Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/7/2026PLURPluri Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/16/2026PLURPluri Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/2/2026PLURPluri Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/19/2026PLURPluri Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/15/2026CLRBCellectar Biosciences LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy5/5/2026CLRBCellectar Biosciences Roth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.005/1/2026PLURPluri Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)(Data available from 7/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLRBCellectar BiosciencesN/AN/AN/AN/A$1.89 per shareN/ACVMCel-SciN/AN/AN/AN/A$2.32 per shareN/AINBPIntegrated BioPharma$54.35M0.09$0.07 per share2.39$0.66 per share0.25PLURPluri$1.08M18.50N/AN/A($0.11) per share-16.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLRBCellectar Biosciences-$21.79M-$6.66N/AN/AN/AN/A-349.24%-153.18%8/13/2026 (Estimated)CVMCel-Sci-$25.41M-$9.77N/AN/AN/AN/A-274.86%-126.47%N/AINBPIntegrated BioPharma$810K-$0.07N/AN/AN/A-3.43%-8.32%-6.57%N/APLURPluri-$22.58M-$4.53N/AN/AN/A-2,162.08%N/A-106.59%9/23/2026 (Estimated)Latest INBP, CVM, CLRB, and PLUR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026CLRBCellectar Biosciences-$0.55N/AN/AN/A$12.00 millionN/A5/15/2026Q2 2026CVMCel-SciN/A-$0.67N/A-$0.67N/AN/A5/14/2026Q1 2026CLRBCellectar Biosciences-$1.8850-$1.33+$0.5550-$1.33$8.00 millionN/A5/14/2026Q3 2026PLURPluri-$0.66-$0.55+$0.11-$0.55$0.66 million$0.17 million5/8/2026Q3 2026INBPIntegrated BioPharmaN/A-$0.03N/A-$0.03N/A$10.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCLRBCellectar BiosciencesN/AN/AN/AN/AN/ACVMCel-SciN/AN/AN/AN/AN/AINBPIntegrated BioPharmaN/AN/AN/AN/AN/APLURPluriN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLRBCellectar BiosciencesN/A1.901.90CVMCel-Sci0.640.600.54INBPIntegrated BioPharmaN/A3.251.78PLURPluriN/A0.330.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLRBCellectar Biosciences16.41%CVMCel-Sci12.08%INBPIntegrated BioPharma25.25%PLURPluri16.59%Insider OwnershipCompanyInsider OwnershipCLRBCellectar Biosciences2.58%CVMCel-Sci14.06%INBPIntegrated BioPharma67.40%PLURPluri43.16%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLRBCellectar Biosciences107.99 million7.79 millionNo DataCVMCel-Sci4317.48 million15.02 millionOptionableINBPIntegrated BioPharma15030.98 million10.10 millionNot OptionablePLURPluri15010.79 million6.13 millionNo DataINBP, CVM, CLRB, and PLUR HeadlinesRecent News About These CompaniesPluri (NASDAQ:PLUR) Trading 3.3% Higher - Should You Buy?July 18, 2026 | americanbankingnews.comPluri in ongoing talks to extend EIB financingJuly 17, 2026 | theglobeandmail.comPluri Chairman Alejandro Weinstein’s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30%July 14, 2026 | markets.businessinsider.comPluri Receives Nasdaq Non-Compliance Notice, Faces Delisting RiskJuly 13, 2026 | tipranks.comLab-grown coffee and chocolate could save both industriesJune 26, 2026 | msn.comPluri Secures Insider Advance Subscription to Boost LiquidityJune 22, 2026 | tipranks.comPlurilock Announces Results of Annual General MeetingJune 16, 2026 | newsfilecorp.comNPluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products ListingJune 2, 2026 | globenewswire.comPluri in Good-Faith Talks on EIB Loan ResolutionJune 1, 2026 | tipranks.comPluri Inc. (PLUR): One of the Premier Lab-Grown Meat Stocks to Invest InMay 31, 2026 | uk.finance.yahoo.comPluri Insider Ups Holding During YearMay 28, 2026 | finance.yahoo.comPluri Analyst Ratings and Price Targets | NASDAQ:PLUR | BenzingaMay 19, 2026 | benzinga.comNewcelX and Eledon Pharmaceuticals Collaborate on NCEL-101 for Type 1 Diabetes, Reporting Strong Financial Position and Strategic Growth PlansApril 30, 2026 | quiverquant.comQPluri Announces Financing Through Unregistered Equity Securities DealMarch 27, 2026 | tipranks.comPluri Inc.: Pluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private PlacementMarch 26, 2026 | finanznachrichten.dePluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private PlacementMarch 26, 2026 | finance.yahoo.comPluri Regains Nasdaq Compliance, Restoring Listing StabilityMarch 2, 2026 | tipranks.comPluri Biotech Secures China Patent for Immune Cell TechFebruary 18, 2026 | contractpharma.comCPluri Secures Global IP Position with China Patent Grant for Large-Scale Immune Cell Expansion, Complementing Prior U.S. PatentFebruary 18, 2026 | markets.businessinsider.comPluri's cell therapy to extends lifespan and combat chronic diseaseFebruary 17, 2026 | i24news.tvINew MarketBeat Followers Over TimeMedia Sentiment Over TimeINBP, CVM, CLRB, and PLUR Company DescriptionsCellectar Biosciences NASDAQ:CLRB$2.47 -0.11 (-4.26%) Closing price 04:00 PM EasternExtended Trading$2.52 +0.05 (+2.23%) As of 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.Cel-Sci NYSEAMERICAN:CVM$1.23 -0.02 (-1.60%) Closing price 04:10 PM EasternExtended Trading$1.24 +0.01 (+1.06%) As of 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.Integrated BioPharma OTCMKTS:INBP$0.16 +0.00 (+2.31%) As of 03:52 PM EasternIntegrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.Pluri NASDAQ:PLUR$1.85 -0.10 (-5.13%) Closing price 04:00 PM EasternExtended Trading$1.85 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Robotaxi Mode Engaged: Tesla Starts Monetizing Its Florida Fleet Insider Moves Are Sending Mixed Signals Across the Tech Sector Boxabl Disrupts Housing With A Tiny Float IPO Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying Velo3D Forges a New Reality After Its Sharp Stock Sell-Off Why Apple Could Be the Last One Standing in the Tech Wreck Archer and Anduril Put ACHR Stock on a New Defense Flight Path 3M's Redemption Arc: Can Q2 Earnings Change the Narrative? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
